Advertisement
U.S. markets closed

BioMarin Pharmaceutical Inc. (BMRN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
87.14+0.86 (+1.00%)
At close: 04:00PM EST
85.50 -1.64 (-1.88%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close86.28
Open86.39
Bid87.56 x 800
Ask87.59 x 800
Day's Range85.91 - 88.28
52 Week Range76.02 - 100.38
Volume1,858,562
Avg. Volume1,498,458
Market Cap16.441B
Beta (5Y Monthly)0.31
PE Ratio (TTM)100.16
EPS (TTM)0.87
Earnings DateApr 24, 2024 - Apr 29, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est108.21
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
25% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BMRN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioMarin Pharmaceutical Inc.
    Analyst Report: BioMarin Pharmaceutical Inc.BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
    Rating
    Fair Value
    Economic Moat
    8 days agoMorningstar
View more